Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285992226> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4285992226 endingPage "S47" @default.
- W4285992226 startingPage "S47" @default.
- W4285992226 abstract "Aphthous ulcers are the most prevalent oral mucosal lesions, yet treatment is challenging. There is evidence that oral montelukast is efficacious in treating aphthous ulcers. A randomized placebo-controlled trial comparing montelukast against prednisone for recurrent aphthous stomatitis demonstrated montelukast has superior efficacy compared with placebo, decreased efficacy compared with prednisone, but decreased adverse effects compared to prednisone. Our single-center, retrospective study identified subjects with a minimum of 2 distinct encounters using the search term:(Singular or montelukast) AND (aphthous ulcers). 16 subjects met inclusion criteria and were found to have follow up after treatment. Over half (56.3%) of patients had positive clinical responses, measured by provider assessment. Among these, 44.4% had reduction in number of ulcers, 22.2% had decrease in frequency of ulcer eruptions, and remainder had unspecified improvement. Mean dosing of montelukast was 9 mg daily, with a range of 4-10 mg. 4-5 mg was prescribed to pediatric patients;10 mg for all others aged 15 and older. While 10% of patients in the aforementioned RCT reported side effect of diarrhea from montelukast, none in our study reported any adverse effects, despite a mean therapy duration of 455.4 days (measured by encounter dates). We were unable to determine an accurate time to response due to longer durations between encounters without specific documentation of time to response. The aforementioned RCT had an active treatment duration of 2 months. Our study demonstrates a longer lasting efficacy of montelukast, as response was measured at the last related encounter. Our study further strengthens support for montelukast as a safe and effective treatment option for recalcitrant aphthous ulcers with reduction in both number and frequency of ulcers. Montelukast has minimal adverse effects, even with long treatment duration, compared with other systemic medications used for management. Further studies to determine the recurrence rate after cessation of montelukast are warranted." @default.
- W4285992226 created "2022-07-21" @default.
- W4285992226 creator A5028486384 @default.
- W4285992226 creator A5053985956 @default.
- W4285992226 creator A5087846564 @default.
- W4285992226 date "2022-08-01" @default.
- W4285992226 modified "2023-09-28" @default.
- W4285992226 title "277 Treatment of aphthous ulcers with montelukast" @default.
- W4285992226 doi "https://doi.org/10.1016/j.jid.2022.05.285" @default.
- W4285992226 hasPublicationYear "2022" @default.
- W4285992226 type Work @default.
- W4285992226 citedByCount "0" @default.
- W4285992226 crossrefType "journal-article" @default.
- W4285992226 hasAuthorship W4285992226A5028486384 @default.
- W4285992226 hasAuthorship W4285992226A5053985956 @default.
- W4285992226 hasAuthorship W4285992226A5087846564 @default.
- W4285992226 hasBestOaLocation W42859922261 @default.
- W4285992226 hasConcept C126322002 @default.
- W4285992226 hasConcept C142724271 @default.
- W4285992226 hasConcept C168563851 @default.
- W4285992226 hasConcept C197934379 @default.
- W4285992226 hasConcept C204787440 @default.
- W4285992226 hasConcept C27081682 @default.
- W4285992226 hasConcept C2776042228 @default.
- W4285992226 hasConcept C2776322731 @default.
- W4285992226 hasConcept C2777288759 @default.
- W4285992226 hasConcept C2778720950 @default.
- W4285992226 hasConcept C2779051857 @default.
- W4285992226 hasConcept C42219234 @default.
- W4285992226 hasConcept C71924100 @default.
- W4285992226 hasConcept C90924648 @default.
- W4285992226 hasConceptScore W4285992226C126322002 @default.
- W4285992226 hasConceptScore W4285992226C142724271 @default.
- W4285992226 hasConceptScore W4285992226C168563851 @default.
- W4285992226 hasConceptScore W4285992226C197934379 @default.
- W4285992226 hasConceptScore W4285992226C204787440 @default.
- W4285992226 hasConceptScore W4285992226C27081682 @default.
- W4285992226 hasConceptScore W4285992226C2776042228 @default.
- W4285992226 hasConceptScore W4285992226C2776322731 @default.
- W4285992226 hasConceptScore W4285992226C2777288759 @default.
- W4285992226 hasConceptScore W4285992226C2778720950 @default.
- W4285992226 hasConceptScore W4285992226C2779051857 @default.
- W4285992226 hasConceptScore W4285992226C42219234 @default.
- W4285992226 hasConceptScore W4285992226C71924100 @default.
- W4285992226 hasConceptScore W4285992226C90924648 @default.
- W4285992226 hasIssue "8" @default.
- W4285992226 hasLocation W42859922261 @default.
- W4285992226 hasOpenAccess W4285992226 @default.
- W4285992226 hasPrimaryLocation W42859922261 @default.
- W4285992226 hasRelatedWork W1511775759 @default.
- W4285992226 hasRelatedWork W1964508636 @default.
- W4285992226 hasRelatedWork W1998759167 @default.
- W4285992226 hasRelatedWork W2018270163 @default.
- W4285992226 hasRelatedWork W2033836503 @default.
- W4285992226 hasRelatedWork W2069946977 @default.
- W4285992226 hasRelatedWork W2107187998 @default.
- W4285992226 hasRelatedWork W2163521166 @default.
- W4285992226 hasRelatedWork W2619141725 @default.
- W4285992226 hasRelatedWork W282266550 @default.
- W4285992226 hasVolume "142" @default.
- W4285992226 isParatext "false" @default.
- W4285992226 isRetracted "false" @default.
- W4285992226 workType "article" @default.